Vitamin D Status and Virologic Response to HCV Therapy in the HALT-C and VIRAHEP-C Trials

Erikka Loftfield, Thomas R O’Brien, Ruth M Pfeiffer, Charles D Howell, Ron Horst, Ludmila Prokunina-Olsson, Stephanie J Weinstein, Demetrius Albanes, Timothy R Morgan and Neal D Freedman

PLOS ONE, 2016, vol. 11, issue 11, 1-17

Abstract: Conclusion: Higher vitamin D status was not beneficially associated with responses to therapy; if anything, patients with higher vitamin D concentrations were less likely to attain SVR. Our data do not support a role for vitamin D supplementation as an adjuvant therapy for HCV.

Date: 2016
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0166036 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 66036&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0166036

DOI: 10.1371/journal.pone.0166036

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().